

Laboratory Service Report

1-800-533-1710

Reference

Patient Name SAMPLEREPORT,CTCB	Patient ID SA00050251	Age 46	Gender F	Order # SA00050251
Ordering Phys				DOB 06/10/1966
Client Order # SA00050251	Account Information			Report Notes
Collected 10/31/2012 13:00	C7028846-DLMP ROCHESTER 3050 SUPERIOR DRIVE			
Printed 11/01/2012 12:57	ROCHESTER,MN 55901			

Test Flag Results Unit Value Site* REPORTED 11/01/2012 12:46 Circulating Tumor Cells, Breast, B Whole Blood Specimen MCR 1059363 Specimen ID MCR Order Date 01 Nov 2012 12:42 MCR Result MCR

Positive, 7 circulating tumor cells/7.5 mL of blood. Interpretation $% \left(1\right) =\left(1\right) \left(1\right)$

The results of this test are positive (> or = 5 circulating tumor cells/7.5 mL of blood).

In patients with metastatic breast cancer, positive results are predictive of shorter progression-free survival (PFS).

In one study of 177 patients with metastatic breast cancer (MBC), CTCs were enumerated before the initiation of a new course of therapy (baseline) and 3-5, 6-8, 9-14, and 15-20 weeks after the initiation of therapy (1). Median progression free survival (PFS) times for patients with <5 CTC from each of the five blood draw time points were 7.0, 6.1, 5.6, 7.0, and 6.0 months, respectively. For patients with > or =5 CTC, median PFS from these same time points was significantly shorter: 2.7, 1.3, 1.4, 3.0, and 3.6 months, respectively. Median overall survival (OS) for patients with <5 CTC from the five blood draw time points was all >18.5 months. For patients with > or =5 CTC, median OS from these same time points was significantly shorter: 10.9, 6.3, 6.3, 6.6, and 6.7 months, respectively. Median PFS and OS times at baseline and up to 9 to 14 weeks after the initiation of therapy were statistically significantly different.

1) Hayes DF et al. Clin Cancer Res 12:4218-4824, 2006. Reason for Referral

Assess for Circulating Tumor Cells

Method

CellSearch (TM) System

Reviewed By Sheila Marie Wilson Release Date 01 Nov 2012 12:44

MCR

MCR

Perform

MCR

MCR MCR

* Performing Site:

MCR Mayo Clinic Laboratories - Rochester Main Campus Lab Director: Franklin R. Cockerill, III, M.D.

Patient Name	Collection Date and Time	Report Status
SAMPLEREPORT,CTCB	10/31/2012 13:00	Final
Page 1 of 1		** End of Report **